Tags

Type your tag names separated by a space and hit enter

GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events.
Respir Res. 2023 Mar 22; 24(1):88.RR

Abstract

New SARS-CoV-2 variants of concern (VOCs) and waning immunity illustrate that quick and easy-to-use agents are needed to prevent infection. To protect from viral transmission and subsequent inflammatory reactions, we applied GlyperA™, a novel antimicrobial formulation that can be used as mouth gargling solution or as nasal spray, to highly differentiated human airway epithelia prior infection with Omicron VOCs BA.1 and BA.2. This formulation fully protected polarized human epithelium cultured in air-liquid interphase (ALI) from SARS-CoV-2-mediated tissue destruction and infection upon single application up to two days post infection. Moreover, inflammatory reactions induced by the Omicron VOCs were significantly lowered in tissue equivalents either pre-treated with the GlyperA™ solution, or even when added simultaneously. Thus, the GlyperA™ formulation significantly shielded epithelial integrity, successfully blocked infection with Omicron and release of viral particles, and decreased intracellular complement C3 activation within human airway epithelial cell cultures. Crucially, our in vitro data imply that GlyperA™ may be a simple tool to prevent from SARS-CoV-2 infection independent on the circulating variant via both, mouth and nose.

Links

PMC Free PDF

Authors+Show Affiliations

Zaderer V
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstrasse 41/R311, 6020, Innsbruck, Austria.
Dichtl S
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstrasse 41/R311, 6020, Innsbruck, Austria.
Posch W
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstrasse 41/R311, 6020, Innsbruck, Austria.
Abiatari I
School of Natural Sciences and Medicine Tbilisi, Ilia State University, Tbilisi, Georgia.
Bonn GK
Austrian Drug Screening Institute (ADSI), Innsbruck, Austria.
Jakschitz T
Austrian Drug Screening Institute (ADSI), Innsbruck, Austria.
Huber LA
Austrian Drug Screening Institute (ADSI), Innsbruck, Austria. Institute of Cell Biology, Biocenter Medical University of Innsbruck, Innsbruck, Austria.
Kurzchalia TV
Dzala LLC, 3 Gotua Str., 0160, Tbilisi, Georgia. t.kurzchalia@dzala.ge.
Wilflingseder D
Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstrasse 41/R311, 6020, Innsbruck, Austria. doris.wilflingseder@i-med.ac.at.

MeSH

HumansCOVID-19SARS-CoV-2EpitheliumNoseInflammation

Pub Type(s)

Letter

Language

eng

PubMed ID

36949547

Citation

Zaderer, Viktoria, et al. "GlyPerA™ Effectively Shields Airway Epithelia From SARS-CoV-2 Infection and Inflammatory Events." Respiratory Research, vol. 24, no. 1, 2023, p. 88.
Zaderer V, Dichtl S, Posch W, et al. GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events. Respir Res. 2023;24(1):88.
Zaderer, V., Dichtl, S., Posch, W., Abiatari, I., Bonn, G. K., Jakschitz, T., Huber, L. A., Kurzchalia, T. V., & Wilflingseder, D. (2023). GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events. Respiratory Research, 24(1), 88. https://doi.org/10.1186/s12931-023-02397-3
Zaderer V, et al. GlyPerA™ Effectively Shields Airway Epithelia From SARS-CoV-2 Infection and Inflammatory Events. Respir Res. 2023 Mar 22;24(1):88. PubMed PMID: 36949547.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events. AU - Zaderer,Viktoria, AU - Dichtl,Stefanie, AU - Posch,Wilfried, AU - Abiatari,Ivane, AU - Bonn,Günther K, AU - Jakschitz,Thomas, AU - Huber,Lukas A, AU - Kurzchalia,Teymuras V, AU - Wilflingseder,Doris, Y1 - 2023/03/22/ PY - 2022/12/23/received PY - 2023/03/13/accepted PY - 2023/3/23/entrez PY - 2023/3/24/pubmed PY - 2023/3/25/medline KW - Antiviral KW - Prophylaxis KW - SARS-CoV-2 KW - Transmission KW - Variants of concern SP - 88 EP - 88 JF - Respiratory research JO - Respir Res VL - 24 IS - 1 N2 - New SARS-CoV-2 variants of concern (VOCs) and waning immunity illustrate that quick and easy-to-use agents are needed to prevent infection. To protect from viral transmission and subsequent inflammatory reactions, we applied GlyperA™, a novel antimicrobial formulation that can be used as mouth gargling solution or as nasal spray, to highly differentiated human airway epithelia prior infection with Omicron VOCs BA.1 and BA.2. This formulation fully protected polarized human epithelium cultured in air-liquid interphase (ALI) from SARS-CoV-2-mediated tissue destruction and infection upon single application up to two days post infection. Moreover, inflammatory reactions induced by the Omicron VOCs were significantly lowered in tissue equivalents either pre-treated with the GlyperA™ solution, or even when added simultaneously. Thus, the GlyperA™ formulation significantly shielded epithelial integrity, successfully blocked infection with Omicron and release of viral particles, and decreased intracellular complement C3 activation within human airway epithelial cell cultures. Crucially, our in vitro data imply that GlyperA™ may be a simple tool to prevent from SARS-CoV-2 infection independent on the circulating variant via both, mouth and nose. SN - 1465-993X UR - https://www.unboundmedicine.com/medline/citation/36949547/GlyPerA™_effectively_shields_airway_epithelia_from_SARS_CoV_2_infection_and_inflammatory_events_ DB - PRIME DP - Unbound Medicine ER -